Multiple System Atrophy — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Prediction models for suicide reattempts by lasso regression through machine learning models: Single versus multiple suicide attempters.
Roberto Natalia et al. — Journal of affective disorders (15 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41702460/
- 2.
Highly biased DNA sequence reconstruction in DNA storage with multi-scale attention mechanism and contrast learning.
Li Xue et al. — Synthetic and systems biotechnology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41783156/
- 3.
Impact of absolute stent expansion on two-year clinical outcomes after PCI in patients with acute coronary syndrome: Results from the OCT-guided PCI registry (TACTICS registry).
Yamamoto Myong Hwa et al. — International journal of cardiology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41765142/
- 4.
Metabolic engineering enables
Poon Nga Yu et al. — Synthetic and systems biotechnology (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41536924/
- 5.
Zero-shot deep learning with multi-objective optimization improves thermostability of zearalenone hydrolase and xylanase.
Wu Fan et al. — New biotechnology (25 May 2026)
https://pubmed.ncbi.nlm.nih.gov/41565015/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
Recruiting — Phase 1 — Arrowhead Pharmaceuticals
https://clinicaltrials.gov/study/NCT06131983
- 2.
Motor Outcomes to Validate Evaluations in Pediatric FSHD (MOVE Peds)
Recruiting — University of Kansas Medical Center
https://clinicaltrials.gov/study/NCT06847282
- 3.
Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1
Recruiting — Phase 1 — Dyne Therapeutics
https://clinicaltrials.gov/study/NCT05481879
- 4.
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT
Recruiting — Phase 2 — Children's Oncology Group
https://clinicaltrials.gov/study/NCT04684368
- 5.
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
Recruiting — Phase 3 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT07225504
- 6.
Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials
Recruiting — Phase 3 — Novartis Pharmaceuticals
https://clinicaltrials.gov/study/NCT05335876
- 7.
Safety of Single and Repeat Dose of PYC-001 Eye Injections in People With Autosomal Dominant Optic Atrophy
Recruiting — Phase 1 — PYC Therapeutics
https://clinicaltrials.gov/study/NCT06970106
- 8.
A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)
Recruiting — Phase 1 — Vertex Pharmaceuticals Incorporated
https://clinicaltrials.gov/study/NCT06185764
- 9.
Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy
Recruiting — Phase 1 — Arrowhead Pharmaceuticals
https://clinicaltrials.gov/study/NCT06138743
- 10.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
- 11.
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia
Recruiting — Phase 2 — St. Anna Kinderkrebsforschung
https://clinicaltrials.gov/study/NCT01949129
- 12.
An International, Multicenter, Prospective Registry on Post-traumatic Long Bones Defects
Recruiting — AO Innovation Translation Center
https://clinicaltrials.gov/study/NCT04112992
- 13.
NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
Recruiting — Phase 2 — NS Pharma, Inc.
https://clinicaltrials.gov/study/NCT05996003
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Multiple System Atrophy
Multiple System Atrophy is a rare and fatal neurodegenerative disease that affects movement, balance, and the autonomic nervous system. It is characterised by alpha-synuclein deposits in glial cells. MSA progresses faster than Parkinson's disease, with median survival of 6-10 years from symptom onset. Diagnosis is challenging and often delayed.
Most Recent Research
The best predictor of a suicide attempt is a previous attempt, apart from psychiatric diagnoses also associated. Some studies found other indicators of great risk for suicide reattempts. Machine Learning algorithms offer the potential for systematic detection of features that carry greater risk for an event. This study sought to develop a classification algorithm distinguishing between Single Suicide Attempters (SSA) and Multiple Suicide Attempters (MSA) in a Spanish multicentre national cohort to explore prediction of subsequent attempts in suicidal patients. Two models including the same sociodemographic and clinical variables grouped in more specific (Model I) or broad (Model II) categories were developed to explore risk factors for suicide reattempts. A Least Absolute Shrinkage and Regression Operator logistic regression with a 10-fold cross-validation was adopted. 1443 adult patients from the SURVIVE cohort were included (582 SSA and 861 MSA). Both Model I (AUC = 0.696; BAC = 0.644) and Model II (AUC = 0.678; BAC = 0.621) outperformed naïve majority-class classification for SSA and MSA. Bipolar disorder type II, binge-eating disorder, and schizophrenia variables weighted heavier on Model I for suicide reattempt-related; while eating disorder diagnosis, Africa as birthplace, affective disorder diagnosis, being employed, schizophrenia-spectrum disorder and substance use disorder diagnoses were the most important suicide reattempt-related of Model II. Affective disorders, eating disorders and schizophrenia-spectrum disorders emerged as the most important variables in predicting reattempts. Both models showed similar sensitivity and specificity when discriminating between SSA and MSA. Identifying specific risk factors for reattempts could have a significant impact on tailoring prevention strategies and interventions.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.